Your search returned 2 results.

Results
	1.	Anti-myeloma activity of MELK inhibitor OTS167: effects on drug-resistant myeloma cells and putative myeloma stem cell replenishment of malignant plasma cells. [electronic resource] by Stefka, A T Park, J-H Matsuo, Y Chung, S Nakamura, Y Jakubowiak, A J Rosebeck, S Producer: 20180406 In: Blood cancer journal vol. 6 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	2.	Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study. [electronic resource] by Jakubowiak, A J Siegel, D S Martin, T Wang, M Vij, R Lonial, S Trudel, S Kukreti, V Bahlis, N Alsina, M Chanan-Khan, A Buadi, F Reu, F J Somlo, G Zonder, J Song, K Stewart, A K Stadtmauer, E Harrison, B L Wong, A F Orlowski, R Z Jagannath, S Producer: 20140310 In: Leukemia vol. 27 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)

Refine your search